Evidence map›Paper›PMID 29181186›Full record

ArticleMolecular and clinical oncology2017

Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients.

Feng Chen, Menghan Yang, Qingkun Song, Jiangping Wu, Xiaoli Wang, Xinna Zhou, Yanhua Yuan, Yuguang Song, Ni Jiang, Yanjie Zhao and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Feng ChenBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Menghan YangBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Qingkun SongBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Jiangping WuBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Xiaoli WangBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Xinna ZhouBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Yanhua YuanBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Yuguang SongBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Ni JiangBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Yanjie ZhaoBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Lei ZhouBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Jun RenBeijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
Beijing Shijitan Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little progress has been made in the treatment of advanced cancer. Dendritic cells (DCs) plus cytokine-induced killer (CIK) cells have exhibited antitumor effects. Thus, the aim of the present study was to evaluate the clinical efficacy of DC-CIK cell treatment in patients with advanced cancer. A paired study including 57 patients treated with DC-CIK cells (DC-CIK group) and 33 patients treated with best supportive care alone (BSC group) was performed. The patients in the DC-CIK group were matched to those in the control group in terms of sex, age, tumor type and clinical stage. T-cell subsets were detected and overall survival (OS) was compared between the two groups. The results demonstrated that CD4

Indexed as

advanced cancercytokine-induced killer cellsdendritic cellsimmunotherapyoverall survivalT-cell subsets

Identifiers

PMID29181186
PMCPMC5700278
OpenAlexW2754544508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.